Lv M, Shen M, Mo X. Development of allogeneic hematopoietic stem cell transplantation in 2022: regenerating “Groot” to heal the world. Innovation. 2023;4:100373. https://doi.org/10.1016/j.xinn.2023.100373.

Article  PubMed  PubMed Central  Google Scholar 

Zhang XH, Chen J, Han MZ, Huang H, Jiang EL, Jiang M, et al. The consensus from the Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14:145. https://doi.org/10.1186/s13045-021-01159-2.

Article  PubMed  PubMed Central  Google Scholar 

Xu LP, Lu DP, Wu DP, Jiang EL, Liu DH, Huang H, et al. Hematopoietic stem cell transplantation activity in China 2020-2021 during the SARS-CoV-2 pandemic: a report from the Chinese Blood and Marrow Transplantation Registry Group. Transplant Cell Ther. 2023;29:136.e131–7. https://doi.org/10.1016/j.jtct.2022.11.011.

Article  CAS  Google Scholar 

Xu LP, Lu PH, Wu DP, Sun ZM, Liu QF, Han MZ, et al. Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplant. 2021;56:2940–7. https://doi.org/10.1038/s41409-021-01431-6.

Article  PubMed  PubMed Central  Google Scholar 

Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH, et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood. 2012;119:5584–90. https://doi.org/10.1182/blood-2011-11-389809.

Article  CAS  PubMed  Google Scholar 

Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125:3956–62. https://doi.org/10.1182/blood-2015-02-627786.

Article  CAS  PubMed  Google Scholar 

Ma YR, Xu LP, Zhang XH, Liu KY, Chang YJ, Lv M, et al. Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings. Ann Hematol. 2021;100:555–62. https://doi.org/10.1007/s00277-020-04359-x.

Article  CAS  PubMed  Google Scholar 

Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175–81.

Article  CAS  PubMed  Google Scholar 

Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100:1525–31.

Article  CAS  PubMed  Google Scholar 

Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol. 2010;11:331–8.

Article  PubMed  Google Scholar 

Jo T, Arai Y, Kondo T, Mizuno S, Hirabayashi S, Inamoto Y, et al. Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients. Cytotherapy. 2022;24:1013–25. https://doi.org/10.1016/j.jcyt.2022.05.009.

Article  PubMed  Google Scholar 

Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer. 2013;119:978–85. https://doi.org/10.1002/cncr.27761.

Article  PubMed  Google Scholar 

Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291–7. https://doi.org/10.1038/sj.bmt.1705445.

Article  PubMed  Google Scholar 

Xu LP, Wu DP, Han MZ, Huang H, Liu QF, Liu DH, et al. A review of hematopoietic cell transplantation in China: data and trends during 2008-2016. Bone Marrow Transplant. 2017;52:1512–8. https://doi.org/10.1038/bmt.2017.59.

Article  CAS  PubMed  Google Scholar 

Zhao X, Gao F, Zhang X, Wang Y, Xu L, Liu K, et al. Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study. Sci China Life Sci. 2016;59:1139–48. https://doi.org/10.1007/s11427-016-0014-8.

Article  CAS  PubMed  Google Scholar 

Xu LP, Liu KY, Liu DH, Chen H, Han W, Chen YH, et al. The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis. Bone Marrow Transplant. 2010;45:985–92. https://doi.org/10.1038/bmt.2009.311.

Article  CAS  PubMed  Google Scholar 

Ma YR, Zhang X, Xu L, Wang Y, Yan C, Chen H, et al. G-CSF-primed peripheral blood stem cell haploidentical transplantation could achieve satisfactory clinical outcomes for acute leukemia patients in the first complete remission: a registered study. Front Oncol. 2021;11:631625. https://doi.org/10.3389/fonc.2021.631625.

Article  PubMed  PubMed Central  Google Scholar 

Mo XD, Zhang YY, Zhang XH, Xu LP, Wang Y, Yan CH, et al. The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. Sci Bull. 2018;63:1376–82. https://doi.org/10.1016/j.scib.2018.08.008.

Article  Google Scholar 

Ma R, Huang XJ, Xu LP, Liu KY, Zhang XH, Yan CH, et al. Comparable outcomes after hematopoietic stem cell transplantation from mother donors and matched unrelated donors in patients with hematopoietic malignancies. Biol Blood Marrow Transplant. 2019;25:1210–7. https://doi.org/10.1016/j.bbmt.2019.01.030.

Article  PubMed  Google Scholar 

Wang Y, Liu QF, Lin R, Yang T, Xu YJ, Mo XD, et al. Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull. 2021;66:2498–505. https://doi.org/10.1016/j.scib.2021.06.002.

Article  CAS  Google Scholar 

Mo XD, Hong SD, Zhao YL, Jiang EL, Chen J, Xu Y, et al. Basiliximab for steroid-refractory acute graft-versus-host disease: a real-world analysis. Am J Hematol. 2022;97:458–69. https://doi.org/10.1002/ajh.26475.

Article  CAS  PubMed  Google Scholar 

Shen MZ, Hong SD, Lou R, Chen RZ, Zhang XH, Xu LP, et al. A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Exp Hematol Oncol. 2022;11:25. https://doi.org/10.1186/s40164-022-00278-x.

Article  PubMed  PubMed Central  Google Scholar 

Fan S, Hong HY, Dong XY, Xu LP, Zhang XH, Wang Y, et al. Machine learning algorithm as a prognostic tool for Epstein-Barr virus reactivation after haploidentical hematopoietic stem cell transplantation. Blood Sci. 2023;5:51–9. https://doi.org/10.1097/bs9.0000000000000143.

Article  PubMed  Google Scholar 

Shen MZ, Hong SD, Wang J, Zhang XH, Xu LP, Wang Y, et al. A predicted model for refractory/recurrent cytomegalovirus infection in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Front Cell Infect Microbiol. 2022;12:862526. https://doi.org/10.3389/fcimb.2022.862526.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134. https://doi.org/10.1186/s13045-017-0502-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. Eur J Haematol. 2016;96:297–308. https://doi.org/10.1111/ejh.12591.

Article  CAS  PubMed  Google Scholar 

Shen MZ, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Preemptive interferon-α therapy could protect against relapse and improve survival of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation: long-term results of two registry studies. Front Immunol. 2022;13:757002. https://doi.org/10.3389/fimmu.2022.757002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan S, Pan TZ, Dou LP, Zhao YM, Zhang XH, Xu LP, et al. Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: a real-world analysis. Front Immunol. 2023;14:1091014. https://doi.org/10.3389/fimmu.2023.1091014.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. https://doi.org/10.1182/blood.2022016867.

Article  CAS  PubMed  Google Scholar 

Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53:1401–15. https://doi.org/10.1038/s41409-018-0204-7.

Article  PubMed  PubMed Central  Google Scholar 

Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706. https://doi.org/10.1002/(sici)1097-0258(19990330)18:63.0.co;2-o.

Article  CAS  PubMed